Clinical Trial Update: A Study of CLN-619 (Anti-MICA/MICB Antibody) in Patients With Relapsed and Refractory Multiple Myeloma [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating CLN-619, an anti-MICA/MICB antibody, in relapsed/refractory multiple myeloma. The study is active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• CLN-619

Snippet

Sponsor: Cullinan Therapeutics Inc. | Conditions: Multiple Myeloma | Phase 1 | Status: ACTIVE_NOT_RECRUITING